Cratal Cardiotonic 20 Tablets
Combined cardiac drugs. ATX code C01E X.
active substances: kratal;
1 tablet contains hawthorn fruit thick extract (Crataegiae fructus extractum spissum) (3.0-3.3: 1), (extractant: ethanol 70% v / v), in terms of dry matter – 43 mg, canine nettle thick extract (Leonuriae herba extractum spissum) (4.5-5.6: 1), (extractant: ethanol 70% v / v), in terms of dry matter – 87 mg, taurine, in terms of 100% dry matter – 867 mg of excipients lattice: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide.
Basic physical and chemical properties:
oval tablets ranged from light gray or light brown to dark brown, speckled, chamfered.
Cratal has a mild cardiotonic, antianginal, antioxidant, antiarrhythmic, antihypoxic, antiplatelet and antiatherogenic effect, reduces the severity of signs of digitalis intoxication, increases efficiency, improves mood, has a calming, neuroprotective effect, inhibits the renin-angiotensin and kallikrein-kinin systems, lipid peroxidation processes, positively affects the production of cyclic adenosine monophosphate (cAMP).
It improves blood supply and the functional state of the myocardium, increases the “coronary reserve”, improves the contractile and pumping functions of the heart muscle, reduces blood pressure and normalizes the heart rate. Cratal reduces the manifestations of digitalis intoxication. Increases efficiency, improves mood, has a calming, neuroprotective effect (eliminates somatonegative disorders – irritability, mood changes).
The components of the drug are almost completely absorbed from the digestive tract. The time for which the maximum concentration of taurine and other components of the drug in the blood is reached is 2:00. Cratal is evenly distributed in tissues and body fluids. Its main amount is excreted in the urine, the half-life is 6-8 hours.
- Neurocirculatory dystonia;
- As part of combination therapy for;
- chronic ischemic heart disease;
- post-radiation syndrome;
- Hypersensitivity to drug components
- Expressed bradycardia and arterial hypotension.
Interaction with other drugs and other types of interactions:
Potentiates the antianginal effects of nitrates, β-blockers, calcium antagonists, antihypoxants, neuroprotectors, cardiac glycosides. Reduces the manifestations of digitalis intoxication. Do not use the drug in conjunction with class III antiarrhythmics, cisapride.
The recommended dose of the drug should not be exceeded. If during treatment the symptoms do not disappear or worsen, you should consult your doctor. If there is swelling of the ankles or legs, pain in the heart region that can spread to the left arm, upper abdomen or neck, or if shortness of breath occurs, you should immediately consult a doctor.
Application during pregnancy or lactation:
There is still no data on the use of the drug during pregnancy or lactation. The drug is contraindicated during pregnancy. If it is necessary to use the drug during lactation, breastfeeding should be discontinued for the period of treatment.
The ability to influence the reaction rate when driving vehicles or other mechanisms:
For the period of treatment, patients who take Kratal should refrain from driving vehicles and potentially dangerous machinery.
Method of administration and dosage:
The duration of treatment and the dose are determined individually. The drug is administered orally, 1-2 tablets are broken 3 times a day before meals. The course of treatment is 3-4 weeks.
There is no experience of using the drug in children.
Symptoms: hypersensitivity reactions, allergic reactions, dyspeptic reactions, general weakness, fatigue, dizziness, drowsiness, arterial hypotension, bradycardia. Treatment: drug withdrawal and symptomatic therapy.
Possible manifestations of hypersensitivity, allergic reactions (including hyperemia, rash, itching, swelling of the skin, urticaria), dyspeptic symptoms, general weakness, increased fatigue, dizziness, drowsiness, hypotension, bradycardia. In case of any undesirable phenomena, the patient should consult a doctor.